Viridian Therapeutics, Inc. VRDN R2K
Healthcare · Biotechnology · United States
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
READ MORE ›$17.62
+26.58% 1Y
Market & Price
Market Cap
$1.95B
Current Price
$17.62
High / Low (52W)
$33.78 / $13.30
Beta
0.82
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$5.79
Price to Book
3.04
P/S
27.44
EV/EBITDA
-3.22
Dividend Yield
-
Profitability & Returns
ROCE
-40.74%
ROE
-58.14%
ROA
-33.25%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.90
EPS (TTM)
$-3.35
Balance Sheet & Liquidity
Debt/Equity
0.08
Quick Ratio
14.71
Current Ratio
15.15
Debt
$53.35M
Total Assets
$899.42M
Current Assets
$894.23M
Working Capital
$823.54M
Ownership
Promoter Holding
0.14%
Chg in Prom Hold
-
FII / Inst Holding
109.73%
Chg in FII Hold
-0.03%
Financial Snapshot
Enterprise Value
$1.24B
Total Revenue (TTM)
$70.92M
EBITDA
$-385.23M
Free Cash Flow
$-182.55M
Operating Cash Flow
$-303.39M
Shares Outstanding
110.43M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
241.95%
Profit 5Y
-54.60%
Revenue (YoY)
95.80%
Earnings (YoY)
-
PROS
- Compounding revenue at 241.9% over 5 years.
CONS
- Earnings shrank at -54.6% CAGR over 5 years.
- Trading 47.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VRDN Viridian Therapeutics, Inc. R2K | 17.62 | - | $1.95B | - | -40.74% | -58.14% | 241.95% | -54.60% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.87M | 1.32M | 1.46M | 1.33M | 2.05M | 2.11M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 72.00K | 75.00K | 70.57M | 132.00K | 141.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 93.94M | 106.84M | 110.58M | 122.88M | 116.31M |
| Operating Income | -1.63M | -2.61M | -2.49M | -3.13M | -3.54M | -3.45M | -4.08M | - | -6.94M | -7.35M | -5.89M | - | -4.62M | -8.86M | -9.15M | - | -11.74M | -8.94M | -11.23M | - | -8.00M | -6.37M | -5.41M | -18.52M | -18.00M | -14.13M | -25.89M | -29.56M | -29.79M | -72.47M | -59.27M | -51.22M | -55.90M | -72.19M | -83.48M | -93.87M | -106.77M | -40.01M | -122.75M | -116.17M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -86.25M | -100.11M | -33.93M | -116.95M | -101.32M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 550.00K | 514.00K | 560.00K | 3.28M | 3.46M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -86.91M | -100.73M | -34.60M | -120.36M | -104.90M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.64M | -2.63M | -2.56M | -3.15M | -3.62M | -3.52M | -4.15M | -5.97M | -6.98M | -7.31M | -5.83M | -6.39M | -4.66M | -8.71M | -9.01M | -10.32M | -11.63M | -8.90M | -11.23M | -10.12M | -8.04M | -6.43M | -5.49M | -18.46M | -17.96M | -14.04M | -25.69M | -29.49M | -28.91M | -68.15M | -55.06M | -47.66M | -48.54M | -64.99M | -76.69M | -86.91M | -100.73M | -34.60M | -120.36M | -104.90M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.82 | -1.48 | -2.91 | -2.21 | -1.25 | -0.98 | -1.06 | -0.86 | -1.61 | -1.27 | -1.09 | -0.79 | -1.02 | -1.15 | -0.87 | -1.00 | -0.34 | -1.08 | -0.90 |
| R&D Expense | 105.00K | 100.00K | 194.00K | 253.00K | 3.47M | 3.35M | 2.96M | 3.91M | 4.12M | 5.49M | 5.02M | 5.00M | 6.41M | 8.38M | 7.40M | 8.23M | 8.75M | 8.60M | 9.03M | 8.42M | 6.10M | 3.84M | 3.11M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.49M | 6.48M | 5.71M | - | - | - | - | - | - | 1.77M | 314.00K | 302.00K | 70.85M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 136.08M | 254.76M | 299.34M | 434.24M |
| Operating Income | -197.00K | -6.87M | -11.19M | -16.99M | -26.53M | -33.08M | -41.98M | -110.38M | - | -134.30M | -254.45M | -299.04M | -363.39M |
| EBITDA | - | - | - | - | - | - | - | - | - | -129.13M | -235.88M | -267.21M | -337.19M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 486.00K | 1.33M | 2.20M | 4.95M |
| Pretax Income | - | - | - | - | - | - | - | - | - | -129.87M | -237.73M | -269.95M | -342.60M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.16M | -7.89M | -11.33M | -17.27M | -26.51M | -32.70M | -41.87M | -110.72M | - | -129.87M | -237.73M | -269.95M | -342.60M |
| Diluted EPS | - | - | - | - | - | - | - | -31.13 | - | -4.05 | -5.31 | -3.07 | -3.32 |
| R&D Expense | 225.00K | 347.00K | 1.00M | 13.69M | 19.62M | 30.42M | 34.79M | - | - | - | - | - | - |
Compounded Sales Growth
| 5 Years: | 241.95% |
| 1 Year: | 95.80% |
Compounded Profit Growth
| 5 Years: | -54.60% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +26.58% |
| 6 Months: | -43.90% |
| 3 Months: | -40.03% |
| 1 Month: | +32.48% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 3.67M | 8.09M | 12.90M | 24.76M | 52.48M | 66.15M | 30.26M | 131.25M | - | 435.09M | 490.42M | 742.40M | 899.42M |
| Current Assets | - | - | - | - | - | - | - | - | - | 431.17M | 486.48M | 738.46M | 894.23M |
| Cash & Equivalents | 209.00K | 5.12M | 21.23M | 22.10M | 47.44M | 32.61M | - | - | - | 155.58M | 102.83M | 99.59M | 212.38M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | 451.00K | 102.00K | 102.00K | 0 | - |
| Total Liabilities | - | - | - | 9.71M | 13.97M | 14.80M | 14.51M | 11.22M | - | 40.03M | 48.40M | 70.76M | 177.25M |
| Current Liabilities | 27.30M | 1.99M | 2.47M | 6.88M | 3.90M | 6.73M | 10.18M | 10.67M | - | 33.35M | 26.64M | 47.87M | 70.70M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | 4.64M | 20.20M | 20.58M | 49.94M |
| Total Debt | - | - | - | - | - | - | - | - | - | 5.26M | 21.05M | 21.09M | 50.69M |
| Total Equity | -23.89M | 5.99M | -45.29M | -61.92M | 38.51M | 51.34M | 15.75M | 120.04M | - | 395.06M | 442.02M | 671.64M | 722.17M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | 41.31M | 53.99M | 80.99M | 101.83M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.17M | -2.21M | -6.90M | -14.76M | -28.17M | -26.84M | -36.06M | -29.78M | - | -93.84M | -184.17M | -232.32M | -276.39M |
| Investing Cash Flow | 6.00K | -274.00K | -95.00K | -250.00K | 1.03M | -29.91M | 28.23M | -50.48M | - | -115.13M | -94.25M | -228.65M | -37.56M |
| Financing Cash Flow | 1.26M | 7.40M | 12.71M | 15.87M | 52.47M | 41.92M | 70.00K | 101.31M | - | 322.24M | 225.67M | 457.74M | 426.74M |
| Capital Expenditure | -5.00K | -266.00K | -123.00K | -250.00K | -246.00K | -445.00K | -84.00K | -42.00K | - | -797.00K | -898.00K | -511.00K | -495.00K |
| Free Cash Flow | -1.17M | -2.48M | -7.02M | -15.01M | -28.41M | -27.29M | -36.14M | -29.82M | - | -94.64M | -185.07M | -232.83M | -276.89M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | 113.28M | -52.75M | -3.23M | 112.79M |
| Share Buybacks | - | - | - | 2.00K | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -3.6% | -105.9% | -196.1% | - | - | - | - | - | - | -7,579.2% | -81,035.0% | -99,018.2% | -512.9% |
| Net Margin % | -39.3% | -121.7% | -198.5% | - | - | - | - | - | - | -7,329.2% | -75,711.5% | -89,387.1% | -483.6% |
| ROE % | 9.0% | -131.7% | 25.0% | 27.9% | -68.8% | -63.7% | -265.8% | -92.2% | - | -32.9% | -53.8% | -40.2% | -47.4% |
| ROCE % | 0.8% | -112.6% | -107.2% | -95.0% | -54.6% | -55.7% | -209.0% | -91.5% | - | -33.4% | -54.9% | -43.1% | -43.9% |
Shareholding Pattern
Insiders
0.14%
Institutions
109.73%
Public Float
109.88%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.92% | 15.38M | $270.98M |
| 2 | Blackrock Inc. | 7.60% | 7.83M | $137.99M |
| 3 | Bellevue Group AG | 6.53% | 6.73M | $118.51M |
| 4 | State Street Corporation | 4.53% | 4.67M | $82.34M |
| 5 | Vanguard Capital Management LLC | 4.04% | 4.17M | $73.43M |
| 6 | Fairmount Funds Management LLC | 3.80% | 3.91M | $68.97M |
| 7 | Venrock Adviser, LLC | 3.77% | 3.88M | $68.41M |
| 8 | Price (T.Rowe) Associates Inc | 3.11% | 3.21M | $56.49M |
| 9 | Paradigm Biocapital Advisors LP | 3.05% | 3.15M | $55.48M |
| 10 | Wellington Management Group, LLP | 2.99% | 3.08M | $54.24M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VRDN
No recent headlines available.